BACKGROUND: Erythropoiesis-stimulating agents (ESAs) have been shown to reduce the need for red blood cell (RBC) transfusions and to improve quality of life for cancer patients with anaemia. However, increased risks of mortality and disease progression have been reported when using ESAs with excessive target haemoglobin levels. In 2007, the United States Food and Drug Administration and Korea Food and Drug Administration issued regulatory alerts for using ESAs in cancer patients. OBJECTIVE: This retrospective study was performed to evaluate changes in ESA prescribing patterns between 2006 and 2010 and the impact on RBC transfusions in patients with solid tumours. SETTING: The Seoul National University Hospital (SNUH) in Korea. METHODS: This study includes adult patients with solid tumours who were diagnosed and treated in the SNUH from January 2006 to December 2010. The exclusion criterion was concomitant chronic renal failure. The patients' Hb levels and prescription data for ESAs and RBC transfusions were statistically analysed. The number of inpatient and outpatient solid-tumour patients was also analysed as a baseline. Main outcome measure Prescription data on ESAs and RBC transfusion. RESULTS: After adjusting for the number of patient visits, the monthly mean ESA doses dispensed decreased by an average of 1,192 mcg per quarter over the last 5 years, and the number of RBC transfusions ordered increased by 3.77 instances per quarter. After correcting for the number of patients, the mean doses of ESA dispensed each month decreased by 3,190 mcg per quarter, and the number of RBC transfusions ordered increased by 9.51 instances per quarter. CONCLUSION: During the last 5 years, the number of ESA doses dispensed at SNUH decreased and the number of RBC transfusions at SNUH increased, independent of the number of patients. The reduction in ESA use was thought to be due to the release of the safety alert letter in 2007. However, this study did not analyse other risk factors that may have influenced the number of RBC transfusions (e.g. metastatic cancer, comorbidities, surgery). Still, the results of this study suggest that the decreased ESA doses were relevant to the increased RBC transfusions.
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) have been shown to reduce the need for red blood cell (RBC) transfusions and to improve quality of life for cancerpatients with anaemia. However, increased risks of mortality and disease progression have been reported when using ESAs with excessive target haemoglobin levels. In 2007, the United States Food and Drug Administration and Korea Food and Drug Administration issued regulatory alerts for using ESAs in cancerpatients. OBJECTIVE: This retrospective study was performed to evaluate changes in ESA prescribing patterns between 2006 and 2010 and the impact on RBC transfusions in patients with solid tumours. SETTING: The Seoul National University Hospital (SNUH) in Korea. METHODS: This study includes adult patients with solid tumours who were diagnosed and treated in the SNUH from January 2006 to December 2010. The exclusion criterion was concomitant chronic renal failure. The patients' Hb levels and prescription data for ESAs and RBC transfusions were statistically analysed. The number of inpatient and outpatientsolid-tumourpatients was also analysed as a baseline. Main outcome measure Prescription data on ESAs and RBC transfusion. RESULTS: After adjusting for the number of patient visits, the monthly mean ESA doses dispensed decreased by an average of 1,192 mcg per quarter over the last 5 years, and the number of RBC transfusions ordered increased by 3.77 instances per quarter. After correcting for the number of patients, the mean doses of ESA dispensed each month decreased by 3,190 mcg per quarter, and the number of RBC transfusions ordered increased by 9.51 instances per quarter. CONCLUSION: During the last 5 years, the number of ESA doses dispensed at SNUH decreased and the number of RBC transfusions at SNUH increased, independent of the number of patients. The reduction in ESA use was thought to be due to the release of the safety alert letter in 2007. However, this study did not analyse other risk factors that may have influenced the number of RBC transfusions (e.g. metastatic cancer, comorbidities, surgery). Still, the results of this study suggest that the decreased ESA doses were relevant to the increased RBC transfusions.
Authors: Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Alessandra Ferrajoli; Aman U Buzdar; Yvette Dejesus; Lee Cheng; Laura B Michaud; Maria A Rodriguez Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: J Seidenfeld; M Piper; C Flamm; V Hasselblad; J O Armitage; C L Bennett; M S Gordon; A E Lichtin; J L Wade; S Woolf; N Aronson Journal: J Natl Cancer Inst Date: 2001-08-15 Impact factor: 13.506
Authors: James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Heinz Ludwig; Jeffrey Crawford; Anders Osterborg; Johan Vansteenkiste; David H Henry; Alex Fleishman; Ken Bridges; John A Glaspy Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544
Authors: Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold Journal: Lancet Date: 2003-10-18 Impact factor: 79.321
Authors: Esther de Vries; Elisabeth Bakker; Remy D C Francisca; Stijn Croonen; Petra Denig; Peter G M Mol Journal: Drug Saf Date: 2022-03-29 Impact factor: 5.228